Innovate U.K., the country's agency designed to foster technology advances, will fund the development of a prototype for a camera-based, remote patient monitoring system from Oxehealth that's ready to be deployed in real-life settings. This comes just as the startup reports positive results from a proof-of-concept study that was also funded in part by the same agency.
Genmab has moved a step closer to seeing daratumumab approved in double refractory multiple myeloma. A rolling submission for the breakthrough cancer therapy is now underway, raising hopes that the product will be on the market early next year.
Targovax is to merge with fellow Nordic biotech Oncos Therapeutics to create an immuno-oncology player with the critical mass to get noticed in the congested and fiercely fought field. The merged company will fuel the first-phase of its ambitions through a private placement, with an IPO in Oslo to follow within the next 12 months.
Researchers from Finland worked with startup Valkee to unveil a bright light headset to treat seasonal affective disorder in 2010. Now it's released placebo-controlled, randomized data about jet lag reduction for its CE-marked headset dubbed the HumanCharger.
Pieris Pharmaceuticals has filed to step up to Nasdaq from OTCQB and add $35 million (€31 million) to its bank balance in the process. The listing would end Pieris' short stay on OTCQB, which began when it acquired Marika in a reverse merger late last year and allowed it to raise $13.5 million in a private placement from investors including OrbiMed Advisors.
Cosmo Pharmaceuticals is pushing ahead with plans to spin out its dermatology assets and list the resulting company on the SIX Swiss Exchange. To get the project underway, Cosmo and its shareholders have clubbed together for a €49.9 million ($56.5 million) capital increase, giving the spinout the cash it needs to wrap up a Phase III trial of its lead candidate.
Biotie Therapies has become the latest European biotech to ratchet up its Nasdaq IPO plans after gauging interest in the offering. But proceeds for the CNS specialist are due to stay at the same level, with the 12% rise in the overall haul coming from UCB's decision to sell its stake for around $7.7 million (€6.8 million).
In this week's EuroBiotech Report, a clutch of European biotechs released oncology trial data at ASCO. MorphoSys posted an early look at the multiple myeloma data on MOR202 everyone has been itching to see since Celgene dropped the drug. And more.
NuCana is set to start a Phase III trial of Acelarin in patients with pancreatic cancerthis month, kicking off a surge into late-stage studies that will see it work on ovarian and biliary programs later this year. The Sofinnova Ventures-backed biotech is initiating the multi-front advance on the strength of Phase I/II data, details of which were presented at ASCO.
Galapagos is moving into new digs on the outskirts of Paris. The relocation sees 130 staff move from three locations across the Biocitech campus Sanofi founded in 2002 to a newly refurbished building on the site that houses a mix of biology and chemistry laboratories.